METASTATIC CERVICAL CANCER
Clinical trials for METASTATIC CERVICAL CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CERVICAL CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CERVICAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Drug attack on cervical cancer enters final testing
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (sac-TMT) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) helps people with metastatic cervical cancer live longer. About 1,000 participants whose cancer has sprea…
Matched conditions: METASTATIC CERVICAL CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental cell therapy targets multiple cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a sin…
Matched conditions: METASTATIC CERVICAL CANCER
Phase: PHASE1 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo therapy offers hope for advanced cervical cancer patients
Disease control Recruiting nowThis study tests a combination of immunotherapy drugs (PD-1/PD-L1 inhibitors) with chemotherapy, with or without bevacizumab, in 120 adults with metastatic, persistent, or recurrent cervical cancer. The goal is to see if this approach helps patients live longer and controls the d…
Matched conditions: METASTATIC CERVICAL CANCER
Phase: PHASE2, PHASE3 • Sponsor: N.N. Alexandrov National Cancer Centre • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New 'seek and destroy' therapy for metastatic cancer enters human testing
Disease control Recruiting nowThis early-stage study tests a two-part system to find and treat metastatic cancer. First, a radioactive tracer is used to spot tumors on a PET scan. Then, a similar radioactive drug is given to deliver radiation directly to the cancer cells. The goal is to see if this approach i…
Matched conditions: METASTATIC CERVICAL CANCER
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo aims to outsmart Drug-Resistant cervical cancer
Disease control Recruiting nowThis phase 2 study is testing whether adding an experimental therapy called PRGN-2009 to the immunotherapy drug pembrolizumab can help shrink tumors in people with recurrent or metastatic cervical cancer that has stopped responding to pembrolizumab alone. About 24 adults with HPV…
Matched conditions: METASTATIC CERVICAL CANCER
Phase: PHASE2 • Sponsor: Precigen, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for advanced cervical cancer: experimental drug SHR-A2102 enters phase 3 trial
Disease control Recruiting nowThis Phase 3 trial is testing a new drug called SHR-A2102 against standard chemotherapy in 398 people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemo and PD-(L)1 inhibitors. The main goal is to see if SHR-A2102 helps people live longer.…
Matched conditions: METASTATIC CERVICAL CANCER
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to shrink advanced cervical tumors
Disease control Recruiting nowThis study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink tumors in people with advanced cervical cancer that has stopped responding to initial treatment. The trial enrolls 35 adults whose cancer has spread or cannot be removed by surgery. The goal is…
Matched conditions: METASTATIC CERVICAL CANCER
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC